BioMatrix Specialty Pharmacy Adds to Growing Family of Companies

BioMatrix Specialty Pharmacy (BioMatrix) offers comprehensive nationwide specialty pharmacy services and digital health technology solutions for a range of chronic health conditions.

BioMatrix recently announced the acquisition of City Drugs Specialty Pharmacy in New York City, NY. As a result of this transaction, BioMatrix broadens their reach in key therapeutic categories with new payer contracts adding additional covered lives and pharmacy staff extensively experienced in rare and chronic health conditions.

The acquisition expands the organization’s national footprint to 12 pharmacy locations nationwide, including:

• Decillion Healthcare
• Elwyn Specialty Care
• Factor Support Network
• Glen Rock Medical Pharmacy
• Med Center Specialty Pharmacy
• Medex Biocare Pharmacy
• OncoSource Rx

City Drugs is located on the Upper East Side of Manhattan and specializes in the treatment of complex medical conditions including hepatitis, oncology, auto-immune diseases, and gastroenterology. City Drugs is accredited by URAC, The Joint Commission, and ACHC for Specialty Pharmacy with a Distinction in Oncology.

BioMatrix also recently announced its newest pharmacy location, BioMatrix of Maryland, significantly expanding its capabilities in oncology and rare and ultra-rare diseases. The Maryland location is an accredited, full-service specialty pharmacy licensed in 50 states, Puerto Rico, and the US Virgin Islands. BioMatrix of Maryland will serve as the focal point for the company’s oncology and rare disease case management, data aggregation, and outcomes monitoring programs.

Takeaway: The acquisition of City Drugs aligns with BioMatrix’s strategic growth in specialty and specialty infusion, expanding its therapeutic mix and increasing our payer access